Temozolomide

Generic Name: Temozolomide

Brand Names: Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva

Drug Type: Small Molecule

Chemical Formula: C_₆H_₆N_₆O_₂

CAS Number: 85622-93-1

Unique Ingredient Identifier: YF1K15M17Y

Background: Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication: Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions: Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome

Associated Therapies: -

Clinical Trials

Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: CNS Tumor, Adult

Interventions: Drug: erlotinib hydrochloride
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2012-12-06

Lead Sponsor: David Peereboom

Target Recruit Count: 27

Registration Number: NCT00274833

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Phase 1

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: arsenic trioxide
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2020-02-25

Lead Sponsor: Northwestern University

Target Recruit Count: 50

Registration Number: NCT00275067

Locations: 🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
Edward Cancer Center, Naperville, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: O6-benzylguanine
Drug: temozolomide

First Posted Date: 2006-01-11

Last Posted Date: 2022-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00275002

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: INO-1001
Drug: temozolomide

First Posted Date: 2006-01-06

Last Posted Date: 2009-03-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 39

Registration Number: NCT00272415

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Phase 1

Active, not recruiting

Conditions: Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Anaplastic Astrocytoma
Adult Mixed Glioma
Adult Anaplastic Oligodendroglioma
Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Vorinostat

First Posted Date: 2005-12-22

Last Posted Date: 2024-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 83

Registration Number: NCT00268385

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 14 locations

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: poly ICLC
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2005-12-07

Last Posted Date: 2019-06-12

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 97

Registration Number: NCT00262730

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 6 locations

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: CP-675,206
Drug: dacarbazine
Drug: temozolomide

First Posted Date: 2005-11-22

Last Posted Date: 2012-07-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 655

Registration Number: NCT00257205

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2005-11-15

Last Posted Date: 2014-01-06

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Registration Number: NCT00253487

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: methylprednisolone
Drug: temozolomide

First Posted Date: 2005-11-04

Last Posted Date: 2018-09-04

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 16

Registration Number: NCT00248534

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Phase 2

Completed

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: temozolomide
Drug: gefitinib
Radiation: radiation therapy

First Posted Date: 2005-10-13

Last Posted Date: 2012-06-05

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 59

Registration Number: NCT00238251

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy